News
Cancer charity starts research programme with drug “borrowed” from industry
BMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39588.708125.DB (Published 22 May 2008) Cite this as: BMJ 2008;336:1155
- Susan Mayor
- 1London
The charity Cancer Research UK announced this week that it has started work on its first clinical research programme in a new partnership arrangement that enables it to “borrow” candidate drugs that have been shelved by drug companies so it can further explore their potential.
The cancer research charity and its commercial arm, Cancer Research Technology, is starting the programme with the clinical development of a tyrosine kinase inhibitor, AZD0424, provided by the drug company AstraZeneca.
Under the terms of the agreement, …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.